文献速递肝病消化道肿瘤与早癌

美国代偿期肝硬化患者接受直接抗病毒药物与干扰素治疗后的肝细胞癌风险比较

Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon.
PubMed 文献 · Aliment Pharmacol Ther · 2025-02-07

该研究基于美国退伍军人医疗系统数据,比较慢性丙型肝炎伴代偿期肝硬化患者接受直接抗病毒药物(DAA)、含干扰素方案或未治疗后的新发肝细胞癌(HCC)风险。结果显示DAA治疗者HCC风险显著低于未治疗者(校正HR 0.70,95%CI 0.65-0.74),DAA与干扰素治疗者之间HCC风险无显著差异(校正HR 0.98,95%CI 0.87-1.10)。

要点

  • DAA治疗者新发HCC风险显著低于未治疗者,校正HR 0.70(95%CI 0.65-0.74)。
  • DAA治疗者与含干扰素治疗者HCC风险无显著差异,校正HR 0.98(95%CI 0.87-1.10)。
  • 研究纳入美国退伍军人医疗系统中慢性HCV感染伴代偿期肝硬化患者。

核心结论

  • 慢性HCV相关代偿期肝硬化患者接受DAA治疗后新发HCC风险较未治疗者降低。
  • DAA治疗者与含干扰素治疗者之间HCC风险无差异。

研究设计与样本

  • 研究识别美国退伍军人事务部医疗系统中慢性HCV感染伴代偿期肝硬化患者,接受干扰素治疗(2005至2013年)或DAA治疗(2013至2017年)。
  • 比较DAA治疗、含干扰素方案或未治疗患者的新发HCC风险,并校正人口学、酒精与药物滥用、合并症、实验室值、医疗利用、既往HCV治疗及HCC监测等差异。
  • 53,847例患者贡献未治疗时间,27,147例贡献DAA治疗时间(其中15,641例同时贡献未治疗与DAA治疗时间),6,809例贡献干扰素治疗时间。

主要发现

  • DAA治疗相关HCC风险显著低于未治疗,校正HR 0.70(95%CI 0.65-0.74)。
  • DAA治疗者与干扰素治疗者HCC风险无显著差异,校正HR 0.98(95%CI 0.87-1.10)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)-infected patients with cirrhosis who received interferon (IFN)-free direct-acting antiviral (DAA) therapy relative to patients who received IFN-containing therapy or remained untreated. AIMS: To estimate the risk of de novo HCC with DAA treatment in cirrhotic HCV patients compared to no anti-HCV treatment and those treated with IFN-based therapy. METHODS: We identified patients with chronic HCV infection and compensated cirrhosis in the US Department of Veterans Affairs healthcare system treated with IFN (2005 to 2013) or DAAs (2013 to 2017). We compared the risk of de novo HCC for patients treated with DAAs, IFN-containing regimens or no treatment after accounting for differences in demographics, alcohol and drug abuse, comorbidities, laboratory values, healthcare utilisation, prior HCV treatment and HCC surveillance. RESULTS: A total of 53,847 patients contributed to untreated time, 27,147 patients contributed to DAA-treated time (15,641 contributed to both untreated and DAA-treated times) and 6809 patients contributed to IFN-treated time. HCC risk associated with DAA treatment was significantly lower than untreated [adjusted HR: 0.70 (95% CI: 0.65-0.74)]. The risk of HCC was not significantly different for patients treated with DAA compared with those treated with IFN [adjusted HR: 0.98 (95% CI: 0.87-1.10)]. CONCLUSIONS: The study shows a reduced risk of de novo HCC among patients with chronic HCV-related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA-treated and IFN-treated patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. El-Serag HB, Duong H, Luster M, et al. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025. PMID: 39921230. doi:10.1111/apt.18525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。